245 related articles for article (PubMed ID: 11121061)
1. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen.
Noursadeghi M; Bickerstaff MC; Gallimore JR; Herbert J; Cohen J; Pepys MB
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14584-9. PubMed ID: 11121061
[TBL] [Abstract][Full Text] [Related]
2. A synthetic lipopolysaccharide-binding peptide based on amino acids 27-39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood.
de Haas CJ; van der Tol ME; Van Kessel KP; Verhoef J; Van Strijp JA
J Immunol; 1998 Oct; 161(7):3607-15. PubMed ID: 9759883
[TBL] [Abstract][Full Text] [Related]
3. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?
Gillmore JD; Hutchinson WL; Herbert J; Bybee A; Mitchell DA; Hasserjian RP; Yamamura K; Suzuki M; Sabin CA; Pepys MB
Immunology; 2004 Jun; 112(2):255-64. PubMed ID: 15147569
[TBL] [Abstract][Full Text] [Related]
4. Survival of Streptococcus pyogenes within host phagocytic cells: a pathogenic mechanism for persistence and systemic invasion.
Medina E; Goldmann O; Toppel AW; Chhatwal GS
J Infect Dis; 2003 Feb; 187(4):597-603. PubMed ID: 12599076
[TBL] [Abstract][Full Text] [Related]
5. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
Quakyi EK; Frasch CE; Buller N; Tsai CM
J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
[TBL] [Abstract][Full Text] [Related]
6. Acute-phase reactants of mice. II. Strain dependence of serum amyloid P-component (SAP) levels and response to inflammation.
Mortensen RF; Beisel K; Zeleznik NJ; Le PT
J Immunol; 1983 Feb; 130(2):885-9. PubMed ID: 6600258
[TBL] [Abstract][Full Text] [Related]
7. Mice lacking serum amyloid P component do not necessarily develop severe autoimmune disease.
Soma M; Tamaoki T; Kawano H; Ito S; Sakamoto M; Okada Y; Ozaki Y; Kanba S; Hamada Y; Ishihara T; Maeda S
Biochem Biophys Res Commun; 2001 Aug; 286(1):200-5. PubMed ID: 11485329
[TBL] [Abstract][Full Text] [Related]
8. Human IgG but not IgM antibodies can protect mice from the challenge with live O6 Escherichia coli.
Pontes GN; Massironi SG; Arslanian C; Palmeira P; Carneiro-Sampaio MM; Nagao AT
Scand J Immunol; 2005 Oct; 62(4):353-60. PubMed ID: 16253122
[TBL] [Abstract][Full Text] [Related]
9. Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis.
Klaerner HG; Dahlberg PS; Acton RD; Battafarano RJ; Uknis ME; Johnston JW; Dunn DL
J Surg Res; 1997 May; 69(2):249-54. PubMed ID: 9224390
[TBL] [Abstract][Full Text] [Related]
10. Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation.
de Haas CJ; van Leeuwen EM; van Bommel T; Verhoef J; van Kessel KP; van Strijp JA
Infect Immun; 2000 Apr; 68(4):1753-9. PubMed ID: 10722560
[TBL] [Abstract][Full Text] [Related]
11. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.
Cox AD; Zou W; Gidney MA; Lacelle S; Plested JS; Makepeace K; Wright JC; Coull PA; Moxon ER; Richards JC
Vaccine; 2005 Oct; 23(43):5045-54. PubMed ID: 16046037
[TBL] [Abstract][Full Text] [Related]
12. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
13. Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection.
Noursadeghi M; Bickerstaff MC; Herbert J; Moyes D; Cohen J; Pepys MB
J Immunol; 2002 Jul; 169(2):913-9. PubMed ID: 12097396
[TBL] [Abstract][Full Text] [Related]
14. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis.
Sullivan GW; Fang G; Linden J; Scheld WM
J Infect Dis; 2004 May; 189(10):1897-904. PubMed ID: 15122527
[TBL] [Abstract][Full Text] [Related]
15. Involvement of CD14 and toll-like receptor 4 in the acute phase response of serum amyloid A proteins and serum amyloid P component in the liver after burn injury.
Cho K; Pham TN; Crivello SD; Jeong J; Green TL; Greenhalgh DG
Shock; 2004 Feb; 21(2):144-50. PubMed ID: 14752288
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-type plasminogen activator receptor plays a role in neutrophil migration during lipopolysaccharide-induced peritoneal inflammation but not during Escherichia coli-induced peritonitis.
Renckens R; Roelofs JJ; Florquin S; van der Poll T
J Infect Dis; 2006 Feb; 193(4):522-30. PubMed ID: 16425131
[TBL] [Abstract][Full Text] [Related]
17. An immunoprotective monoclonal antibody to lipopolysaccharide.
Kirkland TN; Ziegler EJ
J Immunol; 1984 May; 132(5):2590-2. PubMed ID: 6201551
[TBL] [Abstract][Full Text] [Related]
18. The fate of E. coli lipopolysaccharide after the uptake of E. coli by murine macrophages in vitro.
Duncan RL; Morrison DC
J Immunol; 1984 Mar; 132(3):1416-24. PubMed ID: 6363541
[TBL] [Abstract][Full Text] [Related]
19. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages.
Bijl M; Horst G; Bijzet J; Bootsma H; Limburg PC; Kallenberg CG
Arthritis Rheum; 2003 Jan; 48(1):248-54. PubMed ID: 12528126
[TBL] [Abstract][Full Text] [Related]
20. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
Maeda S
Amyloid; 2003 Aug; 10 Suppl 1():17-20. PubMed ID: 14640037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
